INTERVIEW WITH KENNETH PIENTA
The Biology of Prostate Cancer

INTERVIEW WITH JOAQUIN MATEO
Integrating PARP inhibitors into the Standard of Care for Prostate Cancer - Joaquin Mateo

INTERVIEW WITH SCOTT TAGAWA
Antibody-drug Conjugates for Metastatic Urothelial Carcinoma & 177Lu-PSMA-617 for Progressive mCRPC

INTERVIEW WITH JUNE CHAN
"Eat, Move, Sleep"

Videos
State-of-the-industry video lectures by leading urology experts
Featured Videos

#AUA14 - Treatment practice patterns in metastatic castration-resistant prostate cancer patients prior to receiving sipuleucel-T: Data from PROCEED - Session Highlights

ORLANDO, FL USA (UroToday.com) - During the “Advanced Prostate Cancer II” session, Dr. Matthew Cooperberg presented data from PROCEED, an ongoing Phase 4 registry of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with sipuleucel-T (ST). ST is an immunotherapy that targets prostatic acid phosphatase. While PROCEED is ongoing, baseline demographics and treatment practice patterns were reported. Data from approximately 1 400 patients was included. The majority of patients were Caucasian (87.6%) with a median age of 72 years. Median baseline PSA was 16.1 ng/mL, and 49.9% of patients had Gleason ≥ 8 disease.

auaClose to three-quarters of patients underwent local therapy, the majority with radiation (56.9%) or radical prostatectomy (35.8%). Fifteen percent of patients received prior chemotherapy (12.4% docetaxel). Patients treated in oncology practices more commonly received prior oral anti-androgen (67%) and chemotherapy (19%) compared to patients treated in urology practices (41.7% and 5.9%, respectively). The preliminary data from PROCEED provides a window into current treatment patterns for mCRPC. Dr. Cooperberg concluded that PROCEED will continue to provide useful information for tracking practice patterns and care trends for men with mCRPC prior and subsequent to treatment with ST.

Click HERE to view the poster from this session

Presented by Matthew Cooperberg, MD, MPH at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

University of California, San Francisco USA

Written by Jeffrey J. Tomaszewski, MD, medical writer for UroToday.com

Conference Coverage
 
Recent data from conferences worldwide
  • 2019 Annual Meeting / December 4-6 / Washington, DC
  • 2019 Annual Congress / October 17 - October 20 / Athens, Greece
  • 2019 Annual Meeting / October 3 - October 5 / Aarhus, Denmark
  • 2019 Annual Congress / September 27 - October 1 / Barcelona, Spain
  • 2019 Biennial Meeting / August 29-31 / Basel, Switzerland
  • 2019 Think Tank / August 8-10 / Washington, DC
  • 2019 Annual Meeting / May 31 - June 6 / Chicago, IL
  • 2019 Annual Meeting / May 3-6 / Chicago, IL
Journals
Publications focusing on urologic cancer treatments through original manuscripts
Calendar
Upcoming educational events
January 17-19, 2020 /
ESOU 2020
February 24-27, 2020 /
2nd Nuclear Receptors Conference